Comprehensive Characterisation of the Innovator Product: Targeting Bioequivalent Generics

Abstract

Generic products are cost effective and speedy surrogates for high-priced innovator/branded products. The prerequisite for the development of a generic product is therapeutic equivalence (comprising pharmaceutical equivalence and bioequivalence) to the innovator product, thus ensuring comparable efficacy and safety profile. The probability of successfully developing a bioequivalent product can be improved by developing a formulation equivalent to the reference listed drug (RLD), in terms of the quantitative, solid-state characteristics of the active pharmaceutical ingredient (API) and the manufacturing process. This can be achieved by a systematic and thorough characterisation of the RLD. The present study was aimed at developing a methodology for characterisation of ranitidine hydrochloride tablets, with special emphasis on the solid-state characterisation of the API in the tablet.

A differential solubility method was employed for the separation and quantification of excipients present in the tablet. Solid-state properties were characterised using a range of microscopic, thermal, spectroscopic and crystallographic techniques. In addition, results were confirmed by preparing inhouse tablets of the polymorphic forms I and II, using the decoded quantitative formula.

Keywords

generic innovator therapeutic equivalence solid-state characterisation

Get full access to this article

View all access options for this article.

References

Jones

A.C.

(2003) ‘When in-licensing pays’ Scrip Magazine Vol. 123, pp. 13–15.

Milne

C.P.

Cairns

(2003) ‘Generic drug regulation in the US under the Hatch–Waxman act. A balance between competition and innovation or confusion and intrigue?’ Pharm. Dev. Regul. Vol. 1, pp. 11–27.

Jacob

W.F.

Kwak

Y.H.

(2003) ‘In search of innovative techniques to evaluate pharmaceutical R&D projects’ Technovation Vol. 23, No. 4, pp. 291–296.

Peny

J.M.

(2003) ‘How bright is the future for generics?’ Scrip Magazine Vol. 122, pp. 13–17.

Anon. (2004) ‘Below average growth rates for top firms in 2003’, SCRIP daily, April, pp. 1–3.

http://www.imshealth.com; http://www.eyeforpharma.com, accessed in December 2004.

Bansal

A.K.

Koradia

(2004) ‘Role of reverse engineering in the development of generic formulations’, Pharm. Tech., (in press).

Physician's Desk Reference (2003) Thomson Montvale, NJ.

Nachaegari

S.K.

Bansal

A.K.

(2002) ‘High functionality excipient for solid dosage forms’, Business Briefings, September, pp. 38–44.

10.

Nachaegari

S.K.

Bansal

A.K.

(2004) ‘Co-processed excipients for solid dosage forms’ Pharm. Tech. Vol. 28, pp. 52–64.

11.

Brittain

H.G.

Bogdanowich

S.J.

Bugay

D.E.

(1991) ‘Physical characterization of pharmaceutical solids’ Pharm. Res. Vol. 8, pp. 963–973.

12.

Yamamura

Momose

(2001) ‘Quantitative analysis of crystalline Pharmaceuticals in powders and tablets by a pattern-fitting procedure using X-ray diffraction data’ Int. J. Pharm. Vol. 212, pp. 203–212.

13.

Stephenson

G.A.

Forbes

R.A.

Reutzel-Edens

S.M.

(2001) ‘Characterization of the solid state: Quantitative issues’ Adv. Drug Deliv. Rev. Vol. 48, pp. 67–90.

14.

Brittain

H.G.

(1999) ‘Methods for the characterization of polymorphs and solvates’, in Brittain

H.G.

(Ed), ‘Polymorphism in Pharmaceutical Solids’, Marcel Dekker, New York, NY, pp. 228–278.

15.

Carstensen

J.T.

Franchini

M.K.

(1995) ‘Isoenergic polymorphs’ Drug Dev. Ind. Pharm. Vol. 21, pp. 523–536.

16.

Burger

(1982) ‘Thermodynamic and other aspects of the polymorphism of drugs’ Pharm. Int. Vol. 3, pp. 158–163.

17.

Cholerton

T.J.

Hunt

J.H.

Klinkert

Smith

M.M.

(1984) ‘Spectroscopic studies on ranitidine — Its structure and the influence of temperature and pH’. J. Chem. Soc. Perkin Trans. II, pp. 1761–1766.

18.

Hohnjec

Kuftinec

Malnar

(1986) ‘Ranitidine’, in Florey

(Ed), ‘Analytical Profiles of Drug Substances’, Academic Press, New York, NY, pp. 533–561.

19.

Phadnis

N.V.

Cavatur

R.K.

Suryanarayanan

(1997), ‘Identification of drugs in pharmaceutical dosage forms by X-ray powder diffractometry’ J. Pharm. Biomed. Anal. Vol. 15, pp. 929–943.

20.

Raw

A.S.

Furness

M.S.

Gill

D.S.

(2004) ‘Regulatory considerations of pharmaceutical solid polymorphism in abbreviated new drug applications (ANDAs)’ Adv. Drug Deliv. Rev. Vol. 56, pp. 397–414.